

Transcranial Magnetic Stimulation Request Form

Instructions: Please complete all sections to assist with timely review. Fax completed form to **844-442-8012**.

Care manager name:	Reference number:	
Member name:	ID number:	
Member DOB:	Current age:	
Member address:	Member contact phone:	
D (1 T 111 (1 O))	1.41 (TREO) (C) 1.6	
Requesting Transcranial Magnetic Sti		
Physician's name:	Phone number:	
Provider NPI:	Provider Tax ID:	
Office manager name:	Phone number:	
Office address:		
Outpatient practitioner's information (if different from TMS physician)	
Psychiatrist's name:	Phone number:	
r sychianist s hame.	Priorie number.	
Therapist's name:	Phone number:	
Please check all that apply:		
☐ Request is for TMS of the brain.		
☐ Individual is an adult.		
☐ Individual has a confirmed diagnosis of sevel episode.	re major depressive disorder (MDD) single or recurrent	
☐ TMS is requested for treatment of a disorder	other than severe MDD.	
If checked, please specify disorder:		
☐ Individual has failed to significantly respond t	o prior treatment.	
☐ Individual has had four trials of psychopharm	nacologic agents in the current depressive episode.	
☐ Treatment trials have included at least two di effective dose and duration.	fferent agent classes, at or above the minimum	
☐ Treatment trials have included at least two ev	vidence-based augmentation therapies.	
	consisting of one or more drugs, which are not e the efficacy of an antidepressant drug in an adult with dolol to Flouxetine.	

WAAGP-CAID-000769-22 June 2022

☐ Individual is unable to tolerate psychopharmacologic agents as evidenced by four trials with distinct side effects.				
☐ Individual has a history of responses to TMS in a previous depressive episode.				
☐ If individual has a history of TMS, there was a greater than 50% improvements in the individual's symptoms as evidenced by a standard rating scale that reliably measures depressive symptoms. If checked, please mark the rating scale used to document the individual's symptoms:				
☐ Beck Depression Inventory (BDI)				
☐ Geriatric Depression Scale (GDS)				
☐ Hamilton Depression Rating Scale (HAMD)				
☐ Inventory of Depressive Symptomology-Systems Review (IDS-SR)				
☐ Montgomery-Asberg Depression Rating Scale (MADRS)				
☐ Personal Health Questionnaire Rating Scale (PHQ-9)				
☐ Quick Inventory of Depressive Symptomology (QUDS)				
☐ Individual is currently receiving electroconvulsive therapy (ECT), and TMS is considered less invasive.				
☐ Individual is a candidate for and has declined ECT, and TMS is considered a less invasive treatment option.				
☐ Individual has had a trial of an evidence-based psychotherapy known to be effective in the treatment of MDD. If checked, please mark which of the following apply:				
\square Psychotherapy trial had an adequate frequency and duration.				
☐ Psychotherapy trial did not result in a significant improvement in depressive symptoms.				
☐ Individual's depressive symptoms were documented by a standardized rating scale that reliably measures depressive symptoms. If checked, please mark the rating scale used to document their symptoms:				
☐ Beck Depression Inventory				
☐ Geriatric Depression Scale				
☐ Hamilton Depression Rating Scale				
☐ Inventory of Depressive Symptomology-Systems Review				
☐ Montgomery-Asberg Depression Rating Scale				
☐ Personal Health Questionnaire Depression Scale				
☐ Quick Inventory of Depressive Symptomology				
☐ TMS will be administered by a U.S. Food and Drug Administration (FDA) approved device for the treatment of MDD in a safe and effective manner according to the manufacturer's manual.				
If checked, specify device:				
☐ The treatment course will not exceed the following specified stimulation parameters: five days a week for six weeks (total of 30 sessions), followed by a three-week taper of treatments; three TMS treatments the first week, two TMS treatments the following week, and one TMS treatment in the last week.				
☐ Individual has a seizure disorder or history of seizure (except those induced by ECT or isolated febrile seizures in infancy without subsequent treatment or recurrenct).				
☐ Individual has acute or chronic psychotic symptoms or disorders (such as schizophrenia, schizophreniform, or schizoaffective disorder) in the current depressive episode.				
☐ Individual has a neurological condition(s) that includes epilepsy, cerebrovascular disease, dementia,				

increased intracranial pressure, having a history of repetitive or severe head trauma, or primary or secondary tumors in the central nervous system (CNS).					
centimeters from the are not affected by the the following if it appl A cochlea Implanted Pacemake Vagus ner Metal ane Other dev	TMS magnetic co be magnetic field a ies to the individual r implant cardioverter defiber rve simulator (VNS urysm clips or coil ice not listed:	il or other implanted nd are acceptable fo al: rillator (ICD)	device located less that metal items. Note: De or use with TMS. If che	ntal amalgam fillings	
List all current ICD-10	D diagnoses:				
Specific focus of	treatment for	this member			
For the current episode	e of depression, lis	st the medication tria	ls:		
	Date of trial	Maximum dose	Duration of trial	Outcome, side- effects, other relevant info	
If assessed for ECT, why is ECT not being utilized?					
List psychotherapy tr	ials and outcomes	(indicate model of p	svchotherapy used):		
List psychotherapy trials and outcomes (indicate model of psychotherapy used):					
What standardized ra	ating scale of depre	ession was used?			
What were the results (score/range):					
The FDA and manufacturer's user manual specify stimulation parameters of five days per week for six weeks (total of 30 sessions), followed by a three-week taper; three treatments the first week, two treatments the following week, and one treatment the last week. Is the proposed treatment consistent with these parameters? Yes No What is the number of units per week?					
Is this a request for maintenance TMS treatment? ☐ Yes ☐ No					
If so, what is the date of the most recent treatment received?					

You may also submit any additional information relevant to your request for authorization, such as a copy of the TMS intake evaluation or any full psychiatric evaluation done within a three-month period from the requested start of treatment.

By signing below, you are confirming that the information you have provided on this form is accurate and complete based on your clinical assessment of the patient and the records available to you as of the date of this request.

Print MD name:	Date:
Signature:	